Aims Chronic limb-threatening ischaemia (CLTI) entails dismal outcomes and is an absolute
indication to lower extremity revascularization (LER) whenever possible. Antithrombotic …

Aims The role and selection of antithrombotic therapy to improve limb outcomes in chronic
lower extremity artery disease (LEAD) is still debated. We conducted a meta-analysis to …

Objective The optimal antiplatelet regimen after lower extremity revascularization in patients
with chronic limb-threatening ischemia (CLTI) is unknown because current …

Objective Chronic limb threatening ischaemia (CLTI) is the most severe form of peripheral
arterial disease. International guidelines recommend arterial revascularisation in patients …

Objective Although the current guidelines have recommended single antiplatelet therapy
(SAPT) for patients undergoing revascularization for chronic limb-threatening ischemia …

Patients with peripheral artery disease who undergo urgent or emergent lower extremity
revascularization have the highest risk of major adverse cardiac and limb events. Although …

Background: Patients presenting with critical limb-threatening ischemia (CLTI) have been
increasing in number over the years. They represent a high-risk population, especially in …

Background: Patients with peripheral artery disease (PAD) are at heightened risk of acute
limb ischemia (ALI), a thrombotic event associated with amputation, disability, and mortality …

Aims: This study aimed to investigate the long-term impact of guideline-directed medical
therapy (GDMT) on 10-year mortality in patients with chronic limb-threatening ischaemia …

Evidence for antithrombotic treatment following lower extremity revascularization (LER) for
peripheral artery disease (PAD) is limited, leading to weak and conflicting guideline …